Liu Fenyu, Liao Rongrong, Cai Jianhong, Bu Mengru, Xu Ningjun, Zhou Jin
Nursing Department, Integrated Hospital of Traditional Chinse Medicine, Southern Medical University, Guangzhou, China.
Oncology Department, Integrated Hospital of Traditional Chinse Medicine, Southern Medical University, Guangzhou, China.
Asia Pac J Oncol Nurs. 2023 Aug 6;10(10):100291. doi: 10.1016/j.apjon.2023.100291. eCollection 2023 Oct.
Chemotherapy-induced nausea and vomiting (CINV) and retching often pose challenges in managing patients with gastrointestinal cancer. This randomized controlled trial sought to evaluate the effectiveness of press needle therapy in mitigating CINV and retching following chemotherapy.
Two hundred patients with gastrointestinal cancer undergoing folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy were randomly assigned to either the press needle group or the control group. The control group received 5-hydroxytryptamine-3 (5-HT3) antagonists and dexamethasone 30 min before chemotherapy, followed by dexamethasone on days 2 and 3 after chemotherapy. In contrast, the press needle group received press needle treatment 30 min prior to chemotherapy. The primary outcome was the Index of Nausea, Vomiting, and Retching (INVR), assessed at seven time points: before chemotherapy and at 12, 24, 36, 48, 60, and 72 h post-chemotherapy.
All patients completed their respective treatments, and no significant adverse effects related to press needle treatment (such as skin allergies, acupoint infections, headaches, or dizziness) were reported. A two-way repeated-measures analysis of variance (ANOVA) revealed significant differences in INVR scores between the two groups ( < 0.05). Further analysis with a -test indicated that INVR scores in the press needle treatment group were significantly lower than those in the control group at 12, 24, and 36 hours after chemotherapy ( < 0.05), with no significant difference observed thereafter.
Press needle treatment effectively alleviated nausea, vomiting, and retching in patients with gastrointestinal cancer undergoing chemotherapy. It represents a safe, efficient, and convenient complement to preventive treatment with 5-HT3 antagonists.
Chinese Clinical Trial Registry (No. ChiCTR1900024554).
化疗引起的恶心和呕吐（CINV）及干呕在胃肠道癌患者的管理中常常构成挑战。这项随机对照试验旨在评估揿针疗法在减轻化疗后CINV及干呕方面的有效性。
200例接受亚叶酸钙、氟尿嘧啶和奥沙利铂（FOLFOX）化疗的胃肠道癌患者被随机分为揿针组或对照组。对照组在化疗前30分钟接受5-羟色胺-3（5-HT3）拮抗剂和地塞米松治疗，化疗后第2天和第3天再接受地塞米松治疗。相比之下，揿针组在化疗前30分钟接受揿针治疗。主要结局指标是恶心、呕吐和干呕指数（INVR），在七个时间点进行评估：化疗前以及化疗后12、24、36、48、60和72小时。
所有患者均完成了各自的治疗，未报告与揿针治疗相关的显著不良反应（如皮肤过敏、穴位感染、头痛或头晕）。双向重复测量方差分析（ANOVA）显示两组之间的INVR评分存在显著差异（<0.05）。用t检验进一步分析表明，化疗后12、24和36小时，揿针治疗组的INVR评分显著低于对照组（<0.05），此后未观察到显著差异。
揿针治疗有效减轻了接受化疗的胃肠道癌患者的恶心、呕吐和干呕。它是5-HT3拮抗剂预防性治疗的一种安全、高效且便捷的补充方法。
中国临床试验注册中心（注册号：ChiCTR1900024554）
